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LETTERS TO THE EDITORSuccinate Dehydrogenase
Gene Variants and Their
Role in Cowden SyndromeTo the Editor: The TCA Cycle Gene Mutation Database
includes the succinate dehydrogenase (SDH) genes and
was established to catalog the pathogenic mutations of
these genes, which are primarily associated with the
tumors paraganglioma (MIM 168000) and pheochromocy-
toma (MIM 171300). Recently, the database curators have
received expressions of interest in certain SDH mutations
from patients with Cowden Syndrome (CD [MIM
158350]) and clinicians involved in the treatment of the
syndrome, stimulated by a report from Ni et al.1
This paper described germline mutations and variants in
the SDHB (MIM 185470) and SDHD (MIM 602690) genes
in Cowden and Cowden-like (MIM 612359) syndromes.
Ni et al. screened 375 PTEN (MIM 601728) mutation-nega-
tive patients and selected cases for further analysis on the
basis of increased expression of manganese superoxide
dismutase (MnSOD), reasoning that this is a relevant indi-
cator of mitochondrial dysfunction. Within this subset of
74 patients, they found ten individuals with mutations
in SDHB or SDHD. Using a functional approach to address
the question of the pathogenicity of these variants, they
demonstrated that these variants show variable but gener-
ally increased activation of p-Akt and p-MAPK. In addition,
three of the five variants showed increased levels of
reactive oxygen species (ROS). They were not, however,
able to present any genetic data showing the loss of the
wild-type allele in tumors.
A functional screening approach to SDH variants is
welcome, because very few reports of SDH-related muta-
tions show additional experimental data supporting the
pathogenic or benign function of newly reported variants.
The patients with SDH variants also showed a striking
spectrum of tumors, with a significantly different inci-
dence compared to a PTEN-positive cohort.
Although generally clear, this paper left several impor-
tant points unresolved. Was the quantification of func-
tional data based on comparisons to the 18 controls
(Results section) or the 700 controls (mentioned in the
Discussion)? And how were these 18 selected from the
700? Because the entire control cohort of 700 was
sequenced for SDHB, SDHC (MIM 602413), and SDHD,
were the remaining 301 Cowden Syndrome patients also
sequenced? And if so, what was the result of this analysis?
The data presented by Ni et al. suggested that these vari-
ants have a genuine functional role. However, the levels of
p-MAPK and p-Akt activation in carriers of accepted path-
ogenic variants of the SDH genes or in PTEN mutation
carriers were not provided for comparison. Over 700674 The American Journal of Human Genetics 88, 674–676, May 13,normal controls did not show increases in MnSOD,
p-MAPK, or p-Akt, which may indicate that the increases
in p-MAPK or p-Akt are related to MnSOD levels, the selec-
tion criterion for inclusion in this analysis.
Although most of the variants reported by Ni et al. were
already known, none are currently thought to be causative
in paraganglioma or pheochromocytoma, despite being
found in patients. These variants are common. Four out
of five have a reported frequency greater than 1% in
the Single Nucleotide Polymorphism database (dbSNP)
(Table 1), and four out of five are predicted to be benign
by in silico analysis, using current versions of Polyphen
and SIFT (Polyphen-2 and SIFT BLink).2,3 In the routine
clinical genetic analysis of rare syndromes, common vari-
ants are generally considered to be benign under the
assumption that, because no evolutionary selective pres-
sure is operative against a variant, it cannot be deleterious.
So should we now reconsider this paradigm and reassess
these variants in paraganglioma/pheochromocytoma
syndrome? Or could these variants represent a new class
that predisposes exclusively to Cowden Syndrome?
Ni and colleagues stressed the fact that although these
variants are common in certain Western populations,
they are rare in their control population of Northern Euro-
pean descent. This raises the question of the frequency of
Cowden and Cowden-like syndromes in certain European
populations. Although Cowden syndrome has a reported
prevalence of 1 in 200,000 or less,4 components of the
syndrome may be underdiagnosed. The frequency of
some of these SDH variants exceeds 1 in 20 in certain
populations, and even assuming that these variants show
reduced penetrance, it is puzzling that Cowden-related
disease is not more frequently recognized.
Can the variants themselves provide clues to their
specific Cowden-related function? Three of the variants
are located in the mitochondrial transit peptide sequence,
which is generally poorly conserved, varies between 20
and 60 amino acids in length, and is most clearly charac-
terized by a positive net charge of þ3 to þ6, indicating
considerable flexibility in the exact amino acid composi-
tion.5 The remaining SDHB variant, c.487T>C, p.Ser163-
Pro, is located in a poorly conserved region of exon 5,6
with few other missense variants, indicating that this
region plays no vital role in protein structure or function.
The only rare variant identified in this study, SDHD
c.433C>A, p.His145Asn, is located at the border of the
third transmembrane domain and thus resembles the
well-known pathogenic variant c.274G>T, p.Asp92Tyr,
and several other missense variants, which are located at
the borders of transmembrane domains. However, Poly-
phen analysis indicates that the asparagine (Asn) residue
is a benign variant, and SIFT analysis indicates that this is
the most tolerated of possible amino acid changes at this
position (0.46), little different to a synonymous variant.2011














SDHB c.8C>Ga p.Ala3Gly 1.2 1.3 normal no transit peptide bef/be 1.0%–5.1%d,e rs11203289
SDHB c.487T>Ca p.Ser163Pro 2.7 1.7 increased no none be/be 2.2%–5.4%e rs33927012
SDHD c.34G>Ab p.Gly12Ser 1.9 1.9 increased no transit peptide be/be 2.2%–2.4%e rs34677591
SDHD c.149A>Gb p.His50Arg 2.0 1.7 increased no transit peptide pdg/be 1.4%–5.4%e rs11214077
SDHD c.433C>Ab p.His145Asn 1.0 1.2 normal yes none be/be 0.0% not reported
a SDHB RefSeq NG_012340.1.
b SDHD RefSeq NG_012337.1.
c Fold-change, data reported by Ni et al.
d Reported by Burnichon et al.,direct submission to TCA Cycle Gene Mutation Database. Variant also found in Kalahari bushman, indicating an ancient
polymorphism.
e dbSNP (heterozygosity was calculated from the allele frequencies with the Hardy-Weinberg formula).
f Benign.
g Probably damaging.Although these variants clearly fail to comply with stan-
dard criteria for suspected pathogenic SDH mutations,
could they be playing a subtle role in mitochondrial
protein targeting or have a mild effect on protein function,
thereby explaining the lack of bona fide pathogenic
mutations in this analysis of Cowden patients? Although
the data of Ni et al. suggest that these variants may affect
downstream molecules of the PTEN pathway, further
research should focus on the exact effect of these variants
on SDH protein targeting and the stability or turnover of
the SDH complex before definitive conclusions can be
drawn on the pathogenicity of these variants. The TCA
Cycle Gene Mutation Database currently lists these vari-
ants as nonpathogenic, but additional experimental
evidence could lead to a reconsideration of this status.
The study by Ni et al. presents a cohort of Cowden
syndrome-related patients with a striking frequency of
SDHB and SDHD gene variants and suggests that their
results have important implications for patient care and
genetic counseling. Although the data presented are
intriguing and represent a platform for further explora-
tion of the possible functional role of these variants, the
independent confirmation of this report is imperative
before any general recommendations can be made. In
light of the high frequency of these variants in many pop-
ulations, the adequate comprehension of their clinical
significance and thus appropriate counseling will be
very challenging.
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